Matches in DBpedia 2016-04 for { ?s ?p "AS Grindeks is a Latvian company listed on the Riga OMX exchange with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997. One of the key drugs for Grindeks is Mildronate. Mildronate is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.In 2009, Grindeks had a turnover revenue of € 76,2 million with a profit of € 5,078 million. Grindeks had 836 employees and the main shareholders were Kirovs Lipmans (33.29%) and Anne Lipmane (16.69%)"@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Grindeks abstract "AS Grindeks is a Latvian company listed on the Riga OMX exchange with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997. One of the key drugs for Grindeks is Mildronate. Mildronate is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.In 2009, Grindeks had a turnover revenue of € 76,2 million with a profit of € 5,078 million. Grindeks had 836 employees and the main shareholders were Kirovs Lipmans (33.29%) and Anne Lipmane (16.69%)".
- Q2071602 abstract "AS Grindeks is a Latvian company listed on the Riga OMX exchange with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997. One of the key drugs for Grindeks is Mildronate. Mildronate is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.In 2009, Grindeks had a turnover revenue of € 76,2 million with a profit of € 5,078 million. Grindeks had 836 employees and the main shareholders were Kirovs Lipmans (33.29%) and Anne Lipmane (16.69%)".